Invesco Ltd. Boosts Stake in Artivion, Inc. (NYSE:AORT)

Invesco Ltd. raised its holdings in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 22.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 267,067 shares of the company's stock after acquiring an additional 49,462 shares during the period. Invesco Ltd. owned approximately 0.64% of Artivion worth $7,635,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AORT. Lord Abbett & CO. LLC bought a new position in shares of Artivion in the third quarter valued at $5,798,000. Tidal Investments LLC lifted its position in shares of Artivion by 602.2% during the 3rd quarter. Tidal Investments LLC now owns 157,002 shares of the company's stock valued at $4,179,000 after acquiring an additional 134,642 shares during the period. JPMorgan Chase & Co. raised its stake in Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company's stock valued at $2,606,000 after purchasing an additional 78,120 shares in the last quarter. Barclays PLC boosted its position in shares of Artivion by 346.3% during the 3rd quarter. Barclays PLC now owns 70,877 shares of the company's stock worth $1,888,000 after acquiring an additional 54,996 shares in the last quarter. Finally, New Age Alpha Advisors LLC bought a new stake in Artivion during the fourth quarter worth $1,493,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Trading Down 1.1 %

Shares of AORT traded down $0.26 during mid-day trading on Wednesday, reaching $23.73. The company's stock had a trading volume of 347,191 shares, compared to its average volume of 300,475. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The company's fifty day moving average price is $24.17 and its two-hundred day moving average price is $27.26. The stock has a market cap of $1.01 billion, a PE ratio of -1,186.50 and a beta of 1.65. Artivion, Inc. has a 52 week low of $19.36 and a 52 week high of $32.33.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). The company had revenue of $97.31 million during the quarter, compared to analysts' expectations of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Artivion

In related news, SVP Jean F. Holloway sold 5,335 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now directly owns 149,799 shares of the company's stock, valued at approximately $4,091,010.69. This represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John E. Davis sold 6,457 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $176,340.67. Following the sale, the insider now directly owns 160,631 shares in the company, valued at $4,386,832.61. The trade was a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,799 shares of company stock worth $2,356,223. Company insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Needham & Company LLC lowered their target price on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion currently has an average rating of "Buy" and a consensus target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.